Nomination of Dr. Kaushik Majumdar as GPI’s Interim Executive Director
18.7.2022 10:00:00 EEST | Business Wire | Press release
The Global Phosphorus Institute (GPI) announced on June 16th 2022 the designation of Dr. Kaushik Majumdar as Interim Executive Director, with missions of operationalization of current Projects & Activities and further development of GPI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005057/en/
Dr. Kaushik Majumdar Interim Executive director of GPI (Photo: AETOSWire)
“We are pleased to welcome Kaushik at GPI to direct and develop further this global initiative,” said Hicham El Habti, the President of Mohammed VI Polytechnic University, Morocco (UM6P) and President of the GPI. “Having followed the developments made by Kaushik in the frame of other initiatives, I am convinced that with his extensive experience, he will highly contribute to move GPI forward significantly”.
As a recognized leader in agricultural development, Dr. Kaushik Majumdar brings over two decades of experience in building sustainable agricultural systems through his focus on crop nutrition research, extension and capacity building. Most recently in 2019, Dr. Majumdar led the establishment of African Plant Nutrition Institute (APNI) as its Director General, a position he will continue to hold. Before APNI, Dr. Majumdar was the Vice President of Asia and Africa Programs with the International Plant Nutrition Institute, where he coordinated plant nutrition research and outreach activities in China, Southeast Asia, South Asia, and Africa. Dr. Majumdar’s work in Africa and Asia has fostered effective teams, partnering and resource mobilization for improved sustainability within the most vulnerable of food production systems in the world. Dr. Majumdar is also an active influencer of policy through his contributions to the scientific literature and speaking forums.
“I look forward to leading GPI’s vision to engage stakeholders in the discussion about phosphorus stewardship and its role in addressing some of the most critical issues related to food systems resilience, global nutrition and environmental sustainability,” said Dr. Majumdar.
This appointment follows the resignation of the former Executive Director, Dr.Amit Roy.
Dr. Amit Roy decided to resign, with effective date 16th June 2022, to devote his time to activities related to Food and Fertilizer Securities, particularly in Less Developed Countries.
About GPI
The Global Phosphorus Institute (GPI) is a global organization with a holistic vision, footprint and participation to ensure responsible use of phosphorus through cutting-edge science and stakeholder dialogue.
It was launched on June 2nd, 2021 by Mohammed VI Polytechnic University (UM6P) and Ibn Rochd Foundation for Science and Innovation (FIRSI) both based in Morocco.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005057/en/
Contact information
Anas Aguenaou
Anas.Aguenaou@tgpi.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release
Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release
Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 14:30:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesi show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 14:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom